Premium
Pharmacodynamics of daily subcutaneous recombinant human interleukin‐3 in normal volunteers
Author(s) -
Huhn Richard D.,
Yurkow Edward J.,
Kuhn John G.,
Clarke Laura,
Gunn Han,
Resta Debra,
Shah Reena,
Myers Laurie A.,
Seibold James R.
Publication year - 1995
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1016/0009-9236(95)90263-5
Subject(s) - pharmacokinetics , medicine , pharmacodynamics , adverse effect , eosinophil , subcutaneous injection , pharmacology , recombinant dna , granulocyte macrophage colony stimulating factor , toxicity , area under the curve , cytokine , biology , asthma , gene , biochemistry
Normal volunteers received subcutaneous injections of recombinant human interleukin‐3 (rhIL‐3) on 4 consecutive days to characterize toxicity, pharmacokinetics, and hematopoietic effects. Dosage were 2.5, 5.0, and 7.5 μg/kg/day ( n = 6 subjects per group). Adverse effects consisted predominantly of flu‐like symptoms such as fever and headache. Mean area under the serum concentration—time curve and maximum serum concentration were linearly related to dose. Serum clearance was not apparently related to dose. Clearance increased slightly but significantly between days 1 and 4. Rapid but modest elevations in neutrophil and eosinophil counts were observed during treatment. Mean platelet counts rose modestly, peaking on day 10. Increases of CD34 + cell counts were correlated with increases of colony‐forming unit—granulocyte macrophage (peak, day 7). Clinical Pharmacology & Therapeutics (1995) 57 , 32–41; doi: